PRQR ProQR Therapeutics

ProQR Announces Annual Meeting of Shareholders

ProQR Announces Annual Meeting of Shareholders

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the Annual General Meeting of Shareholders will take place on Wednesday, May 19, 2021 at 16:00 CET (10:00am EDT) via videoconference.

All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the “Investors & Media” section of ProQR’s website () under “Financial Information”. The documents will also be made available on the SEC’s website at . Shareholders that wish to attend the videoconference should register as described in the notice and agenda, after which they will receive login details for the videoconference.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at .

ProQR Therapeutics N.V.

Investor Contact:

Sarah Kiely

ProQR Therapeutics N.V.

T:



or

Hans Vitzthum

LifeSci Advisors

T:

Media Contact:

Cherilyn Cecchini, MD

LifeSci Communications

T:



EN
20/04/2021

Underlying

PRQRProQR Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ProQR Therapeutics

 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Second Quarter 2025 Operating and Financial Results

ProQR Announces Second Quarter 2025 Operating and Financial Results Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestones from Lilly partnership LEI...

August 7, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Upcoming Presentation at RNA Editing Summit

ProQR Announces Upcoming Presentation at RNA Editing Summit LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will participate in the RNA Editing Summit taking place July 29-31, 2025, in Boston, MA. “We recently achieved a key milestone with the submission of the CTA for AX-0810, targeting NTCP for cholestatic diseases, and we’re building on this momentum ...

July 28, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting ...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on i...

June 26, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES C...

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Pep...

May 12, 2025 1 EN
 PRESS RELEASE
Free
PRQR ProQR Therapeut...

ProQR Announces First Quarter 2025 Operating and Financial Results

ProQR Announces First Quarter 2025 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch